Evidence map›Paper›PMID 34944746›Full record

ArticleBiomedicines2021

Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma.

Anna Tosi, Lavinia Nardinocchi, Maria Luigia Carbone, Lorena Capriotti, Elena Pagani, Simona Mastroeni, Cristina Fortes, Fernanda Scopelliti, Caterina Cattani, Francesca Passarelli and 4 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Anna TosiDepartment of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy.
Lavinia NardinocchiExperimental Immunology Laboratory, Istituto Dermatopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy.
Maria Luigia CarboneExperimental Immunology Laboratory, Istituto Dermatopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy.ORCID 0000-0002-3350-1210
Lorena CapriottiExperimental Immunology Laboratory, Istituto Dermatopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy.
Elena PaganiMolecular Oncology Laboratory, Istituto Dermatopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy.
Simona MastroeniEpidemiology Unit, Istituto Dermatopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy.
Cristina FortesEpidemiology Unit, Istituto Dermatopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy.
Fernanda ScopellitiIstituto Nazionale per la Promozione della Salute delle Popolazioni Migranti ed il Contrasto delle Malattie della Povertà INMP, 00153 Rome, Italy.
Caterina CattaniIstituto Nazionale per la Promozione della Salute delle Popolazioni Migranti ed il Contrasto delle Malattie della Povertà INMP, 00153 Rome, Italy.
Francesca PassarelliHistopathology Department, Istituto Dermatopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy.
Antonio RosatoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy.ORCID 0000-0002-5263-8386
Stefania D'AtriMolecular Oncology Laboratory, Istituto Dermatopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy.
Cristina Maria FaillaExperimental Immunology Laboratory, Istituto Dermatopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy.ORCID 0000-0001-5991-8914
Andrea CavaniIstituto Nazionale per la Promozione della Salute delle Popolazioni Migranti ed il Contrasto delle Malattie della Povertà INMP, 00153 Rome, Italy.
Istituto Dermopatico dell'Immacolata · ITUniversity of Padua · IT

Funding

Fondazione Veronesi Young Research FelllowshipItalian Government 5XMILLEItalian Ministry of Health RC2018-2021
6 · The paper itself

Abstract

Characterization of tumor associated lymphocytes (TILs) in tumor lesions is important to obtain a clear definition of their prognostic value and address novel therapeutic opportunities. In this work, we examined the presence of T helper (Th)17 lymphocytes in cutaneous melanoma. We performed an immunohistochemical analysis of a small cohort of primary melanomas, retrospectively selected. Thereafter, we isolated TILs from seven freshly surgically removed melanomas and from three basal cell carcinomas (BCC), as a comparison with a non-melanoma skin cancer known to retain a high amount of Th17 cells. In both studies, we found that, differently from BCC, melanoma samples showed a lower percentage of Th17 lymphocytes. Additionally, TIL clones could not be induced to differentiate towards the Th17 phenotype in vitro. The presence or absence of Th17 cells did not correlate with any patient characteristics. We only observed a lower amount of Th17 cells in samples from woman donors. We found a tendency towards an association between expression by melanoma cells of placenta growth factor, angiogenic factors able to induce Th17 differentiation, and presence of Th17 lymphocytes. Taken together, our data indicate the necessity of a deeper analysis of Th17 lymphocytes in cutaneous melanoma before correlating them with prognosis or proposing Th17-cell based therapeutic approaches.

Indexed as

interleukin-17melanomaT-helper 17 lymphocytestumor infiltrating lymphocytes

Identifiers

PMID34944746
PMCPMC8698827
OpenAlexW4200030388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.